Compare NNDM & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNDM | GYRE |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.7M | 625.6M |
| IPO Year | 2015 | 2004 |
| Metric | NNDM | GYRE |
|---|---|---|
| Price | $1.19 | $4.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $18.67 |
| AVG Volume (30 Days) | ★ 1.2M | 178.3K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $102,437,000.00 | $275,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.00 | $27.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 77.30 | N/A |
| 52 Week Low | $1.19 | $3.97 |
| 52 Week High | $2.32 | $9.14 |
| Indicator | NNDM | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 28.94 | 38.23 |
| Support Level | N/A | $3.97 |
| Resistance Level | $1.62 | $7.37 |
| Average True Range (ATR) | 0.06 | 0.56 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 4.53 | 16.13 |
Nano Dimension Ltd provides industrial manufacturing solutions for the design-to-manufacturing of electronics and mechanical parts. These solutions are based on a combination of hardware, software, and materials science technologies. The solutions include industrial machinery, such as those for additive manufacturing, surface-mount technology, and industrial inkjet printing, along with software for design, simulation, and manufacturing management, as well as materials or consumables that are used by the machinery. These solutions are used by industrial customers in aerospace & defense, automotive, electronics, medical, research, and academia, along with government organizations.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.